FDA Determines Regulatory Review Period for TRUQAP Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for TRUQAP, a patent extension application submitted to the US Patent and Trademark Office (USPTO) for a human drug product.